A record-breaking year for innovation
With its highest number of patents issued, commercial agreements, corporate-sponsored research funding, and licensing revenue receipts in a single period, PCI experienced a landmark fiscal year.
Ten years of I-Corps: The program that changed innovation
VentureWell looks back at launch of the National I-Corps program 10 years ago, and what the program has meant to inventors, researchers, and startups.
This tech startup is helping N. Philadelphians take control of their health
The founder, Deboleena (Deb) Dutta graduated from Wharton and participated in the PCI I-Corps program with Viora Health.
$10 Million gift establishes new Colton Center for Autoimmunity at Penn Medicine
Center brings together autoimmune disease researchers and clinicians to advance diagnosis and treatment
I-Corps graduate, Strella Biotechnology, featured in Washington Post story
A featured story on Katherine Sizov, founder of Strella Biotechnology, and how the company's sensors are reducing food waste and fighting climate change.
Penn launches $750M investment in science, engineering, and medicine
President Amy Gutmann has announced the launch of a $750 million investment.
Pennovation Works Celebrates Five Years
November 8, 2021 marked the fifth anniversary of Pennovation Works, Penn’s business incubator and laboratory space.
Celebrating five years of innovation, entrepreneurship, and creativity
Penn Today marks the anniversary of Pennovation Works with a look at the evolution of the site, its research and commercialization achievements, and a glimpse into the future.
After setbacks, cell therapy for glioblastoma moves onto new chapter
At Penn, a leader in GBM cellular therapies since the early days of this technology, a new CAR cell therapy could find its way into clinical trials by next year in collaboration with Tmunity.
NIH, FDA and 15 private organizations join forces to increase effective gene therapies for rare diseases
NIH, FDA, 10 pharmaceutical companies and five non-profit organizations have partnered to accelerate development of gene therapies for rare diseases.